La chaîne d'options affiche les données clés des options sur actions de Ondas Holdings à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Ondas Holdings..

Ondas Holdings (NASDAQ:ONDS) Stock, Chaîne d'Options

Ondas Holdings

Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.

Ondas Holdings Inc

Chardan Capital analyst Rudy Li maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and maintains $55 price target.

News

Price Target

Analyst Ratings

XENE

Chardan Capital Maintains Buy on Xenon Pharmaceuticals, Maintains $55 Price Target

Needham analyst Chris Pierce reiterates Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) with a Buy and maintains $13 price target.

Reiteration

ACHR

Needham Reiterates Buy on Archer Aviation, Maintains $13 Price Target

WIIM

ARWR

Arrowhead Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results.

"We are excited about the opportunites we're seeing across our business and look forward to driving further revenue growth and value for our shareholders in 2025. We continue to expect full year 2025 GAAP EPS to exceed $2.40 per diluted share, and full year 2025 non-GAAP adjusted EPS to exceed $2.80 per diluted share," Mr. Suzuki concluded.

Guidance

BKTI

CORRECTION: BK Technologies Affirm FY25 GAAP EPS Outlook Of More Than $2.40

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) with a Buy and lowers the price target from $50 to $45.

NGNE

HC Wainwright & Co. Maintains Buy on Neurogene, Lowers Price Target to $45

MVST

Microvast Holdings shares are trading higher after the company reported better-than-expected Q1 sales results.

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) with a Buy and maintains $60 price target.

Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target

EXOD

Exodus Movement shares are trading lower after the company reported worse-than-expected Q1 sales results.

GigaCloud Technology shares are trading higher after the company reported better-than-expected Q1 financial results.

INDI

Indie Semiconductor shares are trading lower after the company reported worse-than-expected Q1 sales results.

<ul>
<li>ATTRibute-CM, BridgeBio's Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients (59.1% risk reduction), establishing the mechanistic hypothesis that stabilizing TTR may delay or prevent ATTRv-CM.</li>
<li>ACT-EARLY is a registrational, randomized, double blind, placebo controlled, event driven prevention study that will enroll ~600 asymptomatic carriers of a pathogenic TTR variant. Diagnosis of ATTRv disease will be evaluated as the primary analysis of the study</li>
<li>In the ACT-EARLY study, BridgeBio will partner globally with ATTR amyloidosis treating physicians and patient advocacy organizations with the hope of addressing a serious unmet need and proving that ATTRv can be delayed or prevented.</li>
<li>Acoramidis is approved as Attruby by the U.S. FDA and is approved as BEYONTTRA by the European Commission, Japanese Pharmaceuticals and Medical Devices Agency, and the UK Medicines and Healthcare Products Regulatory Agency</li>
</ul>

Biotech

Health Care

General

BBIO

BridgeBio Pharma Has Dosed The First Asymptomatic Participant With A Known Pathogenic Transthyretin Variant, Which May Lead To Transthyretin Amyloid Disease In ACT-EARLY Study With Acoramidis

3D Systems shares are trading lower after the company reported worse-than-expected Q1 financial results.

Earnings

Earnings Beats

NERV

Minerva Neurosciences Q1 EPS $(0.50) Beats $(1.07) Estimate

The recent relaxation of tariffs between the U.S. and China has sparked a significant market rally, with tech CEOs and founders reaping substantial benefits.
What Happened: The &#8220;magnificent seven&#8221; stocks, including Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), collectively added nearly $830 billion to their market capitalization, as <a href="https://www.forbes.com/sites/dereksaul/2025/05/12/us-china-tariff-thaw-sparks-stock-rally-making-bezos-musk-and-zuckerberg-more-than-40-billion-richer/">per</a> a Forbes report.
Although Tesla's share price, at $318.38, remains below its all-time high of nearly $490, Elon Musk's net worth rose by $15 billion, reaching $359 billion, as per the Bloomberg Billionaire Index. The rally further solidified his position as the world's richest person.
Amazon&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) founder, Jeff Bezos, and Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) CEO, Mark Zuckerberg, also saw their net worth rise by $14 billion and $16 billion, respectively. However, both still trail Musk by nearly $130 billion.
SEE ALSO:&nbsp;<a href="https://benzinga.com/trading-ideas/movers/25/05/45368880/xrp-rallies-over-3-tuesday-morning-is-the-coin-heading-toward-3" target="_blank" rel="noreferrer noopener">XRP Rallies Over 3% Tuesday Morning — Is The Coin Heading Toward $3? &#8211; Benzinga</a>
Why It Matters: The U.S. and China agreed to reduce tariff rates, a move that could propel <a href="https://www.benzinga.com/tech/25/05/45357613/china-tariff-de-escalation-biggest-winners-include-tesla-apple-new-tech-highs-back-on-the-table-now-for-2025">technology stocks </a>to new heights, according to Wedbush&#8217;s Dan Ives. The stock of Amazon climbed 8.07%, Meta Platforms rose 7.92%, while Tesla was up 6.75% on Monday. Tesla, led by Musk, surpassed a $1 trillion valuation for the first time since late February.
The 90-day tariff pause between the U.S. and China has resulted in a market rally and positive sentiment. However, experts warn that this is not a <a href="https://www.benzinga.com/government/regulations/25/05/45367206/sp-500-rallies-over-3-on-us-china-90-day-tariff-truce-but-experts-warn-it-doesnt-guarantee-a-complete-resolution-of-the-trade-war">definitive end</a> to the trade war, leaving significant long-term uncertainty. The news triggered an immediate positive market response, with stocks and oil prices rebounding, potentially leading to lower costs for businesses and consumers.
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45335756/cathie-wood-stands-firm-on-bold-700000-bitcoin-prediction-for-investors-says-bull-case-in-the-1-5-million-range" target="_blank" rel="noreferrer noopener">Cathie Wood Stands Firm on Bold $700,000 Bitcoin Prediction for Investors, Says ‘Bull Case in the $1.5 Million Range&#8217; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Markets

Tech

AAPL

AMZN

NVDA

TSLA

Elon Musk, Jeff Bezos, Mark Zuckerberg Gain Billions As US-China Tariff Truce Boosts Tech Billionaires' Fortunes

POWI

Power Integrations shares are trading lower. The company reported Q1 financial results.

Contracts

V2X Awarded Spot On US Army LTRaC Contract;  LTRaC IDIQ Contract Has A Ceiling Value Of $379M Over An Eight-year Period Of Performance, Including A Five-Year Base And A Three-Year Option Period.

International Game Technology shares are trading lower after the company reported worse-than-expected Q1 financial results and narrowed its FY25 sales guidance.

Bicara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.42) by 61.9 percent. This is a 96.41 percent increase over losses of $(18.94) per share from the same period last year.

Earnings Misses

BCAX

Bicara Therapeutics Q1 EPS $(0.68) Misses $(0.42) Estimate

<a href="https://www.globenewswire.com/Tracker?data=NxiInwnJ0u04ZM_I05yHOCxjuUs5W0PeGG-o8YLNkCpPYn3qbUS4-Z4FAyfvAzje4Xp4vKzxpLcpIcHuddxr2PCwcEvLrRzrEiqNbcFZWf2BwrQalR8p-LMc_d1Kvl05sRd_44NBAv8gs-5axlUferar_sMH-nrT7oKA7jpx-VrXl4Gd1DWqTZ2HGS0MSjtRdpVIYv-WAeRe2D2DqydrvfY0vh1Kzu371HUOi2dySq0=">Caliber</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWD#NASDAQ">CWD</a>), a real estate investor, developer, and manager, today announced the launch of Caliber Hospitality Development, LLC ("CHD"), a joint venture between Caliber and GIA Hospitality, LLC ("GIA"). CHD will serve as the exclusive development platform for Caliber's opportunistic hospitality investments, with a focus on acquiring distressed hotel assets and developing extended stay hotels in high-demand markets.
The joint venture was seeded with an initial $2 million investment from GIA and is supported by Caliber's integrated real estate services, including development, construction, finance, and asset management. CHD will operate independently under the Caliber Hospitality brand.

Caliber Launches Hospitality Venture to Target Distressed Hotels and Extended Stay Markets

ODDITY Tech shares are trading lower after the company announced the sale of 5.5M shares of its Class A ordinary shares by an entitty affiliated with Oran Holtzman

Small Cap

Opinion

Press Releases

US Drone Surveying Market Expected to Realize Double-Digit Market Growth Predicted to Reach $2.54 Billion By 2033

Ondas Secures $3.2 Million Order to Expand the Optimus Drone Infrastructure in the UAE

Drone Surveying Industry Witnessing Continuous Technological Advancements Generating Rising Revenue Opportunity

Despite Volatility in the Markets Global Drone Market Is Expected to Achieve Remarkable Growth as Usage Skyrockets

Association of American Railroads Selects dot16 Protocol Pioneered by Ondas Networks for Next-Generation HOT-EOT ("NGHE") Communications

Multi-Billion Dollar Global Drone Industry Showing Resilience and Adaptability as Further Expansion & Growth Expected

Ondas Secures $3.4 Million Order for Iron Drone Raider Counter-UAS System from Renowned European Defense Contractor for Government Client

Drone-Mounted Lidar Systems for Bathymetric Surveys Market Expected to Reach $890 Million By 2032

Ondas Holdings to Report First Quarter 2025 Financial Results on May 15, 2025 at 8:30 a.m. ET

How the Industry of Drones is Evolving Rapidly with New Trends and Technologies Emerging Regularly

Comments

Ondas Holdings

Ondas Holdings (ONDS) Options

Ondas Holdings (NASDAQ:ONDS) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL